Gostout brings with him more than 30 years of experience in gastroenterology and hepatology with the Mayo Clinic in Rochester, Minnesota, and is a recognised key opinion leader on minimally invasive endolumenal and surgical procedures.
In his new role, Gostout will be responsible for developing the medical and clinical strategy for the company and will be the company's principal representative interacting with key medical societies and other key opinion leaders in the advancement of Apollo's business goals.
Gostout will join the executive management team as a direct report to the company's CEO Todd Newton.
Prior to joining Apollo in this capacity, Gostout grew a successful gastroenterologist practice at the Mayo Clinic, Rochester, Minnesota, in the Division of Gastroenterology and Hepatology, with a joint appointment in the Department of Surgery, from which he retired on December 31, 2016.
In addition to his medical practice, Dr. Gostout previously provided consulting Chief Medical officer services to Apollo.
He was a Professor of Medicine in the Mayo Clinic College of Medicine and the director of the Developmental Endoscopy and Research Unit, and the founder of The Mayo Clinic GI Bleeding Team and the Developmental Endoscopy Unit.
Gostout has previously been the president of the American Society for Gastrointestinal Endoscopy and has been responsible for the development of the renowned ASGE ITT center. He has also been a member of The board of Trustees in the American College of Gastroenterology.
His areas of specialty interest, research, and publication include endoscope development, gastrointestinal bleeding, management of pancreaticobiliary disease, advanced endoscopic imaging, endotherapy of obesity, and endoscopic resection and tissue closure techniques.
Apollo Endosurgery is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 500 m people globally, as well as other gastrointestinal disorders.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients